Segment & Geographic Data Quant-Grade Normalized (live API) API & CSV Delivery

Capsovision Inc's Business Segments

Capsovision Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.

Segment Data As of FY

Reportable Segments

Per the company's own filing, this quarter

Largest Segment

Total Revenue

$ 4

Consolidated, this quarter

Regions Reported

Geographic regions, this quarter

API endpoints for this dataset

                        https://api.csimarket.com/api/v1/companies/CV/segments                    

                        https://api.csimarket.com/api/v1/companies/CV/geographic                    

                        https://api.csimarket.com/api/v1/companies/CV/exposure                    

Programmatic access for models, analytics, and integration workflows.

Pull these exact ratios programmatically

Get an API key License this feed for redistribution / AI →

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Capsovision Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.

Revenue by Product & Service Category - FY

Product75.1%
Service11.4%

Revenue by Product & Service Category - FY

Category	Period	Revenue (Millions)	% of Total
Product	FY	$ 2	75.1%
Service	FY	$ 0	11.4%

Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.

Description of Capsovision Inc

The company develops and sells the CapsoCam Plus capsule, a product for small bowel examination, with current revenues derived solely from its sales. It is pursuing FDA 510(k) clearance for the CapsoCam Colon product and expects sales upon clearance. The company plans to increase small bowel capsule sales by expanding pediatric use and telehealth supervision and is developing related products. It aims to enter new gastrointestinal indications and patient populations, enhance its products and technologies with artificial intelligence capabilities, and expand commercialization efforts domestically and internationally. The company relies on assembly manufacturers and component suppliers and seeks to protect its intellectual property through patents and trade secrets. It has a history of net losses, faces substantial doubt about its ability to continue as a going concern, and requires additional financing to support its business and revenue growth plans. The company operates in a competitive and rapidly changing environment and notes that forward-looking statements about its business, products, and financial performance involve risks and uncertainties that may cause actual results to differ materially.